cagrilintide and semaglutide New in the August 14, 2025, issue of NEJM: ⁣ ⁣ Cagrilintide–Semaglutide for Overweight or Obesity (REDEFINE 1 phase 3a trial)⁣ ⁣ Cagrilintide– for Overweight Diabetes (REDEFINE 2 phase 3a trial)⁣ ⁣ CagriSema(Cagrilintide + Semaglutide) 10mg(5mg+5mg) -

There is a lot of interest in ipamorelin because, unlike other growth hormone releasing peptides, it is extremely targeted to growth hormone with minimal effects on other hormones or biochemical processes [3]

pmid:36771262 28

While the study was observational (meaning that causality cant be confirmed), it does add to the growing body of evidence suggesting that its worth investigating these weight-loss drugs as potential cancer prevention tools, says lead author, Professor Elizabeth McDonald

however, when compared with semaglutide 1.0 mg in type 2 diabetes, in doses of 5 mg, 10 mg and 15 mg, tirzepatide resulted in significantly greater body-weight reductions [5]